Clinical Trials Directory

Trials / Completed

CompletedNCT02194023

Clinical Effects of Two New Chlorhexidine Digluconate Formulations: 0.12% and 0.03%.

Inhibition of de Novo Plaque Formation and Side Effects of Two New Mouthrinse Formulations: 0.12% and 0.03% Chlorhexidine Digluconate, Respectively, in a 4-day Non-brushing Model. A Triple-blind, Randomized Clinical Trial.

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
200 (actual)
Sponsor
Universitat Internacional de Catalunya · Academic / Other
Sex
All
Age
18 Years – 30 Years
Healthy volunteers
Accepted

Summary

In the current study we tested the hypothesis that new 0.05% Cetylpyridinium chloride (CPC) mouthrinse formulations containing 0.12% or 0.03% chlorhexidine digluconate (CHX): 1) yield similar or better clinical results regarding the inhibition of de novo plaque growth compared to those achieved with an already marketed 0.12% CHX mouthrinse (Perio-Aid Treatment without alcohol. Dentaid, Spain), 2) reduce the side effects caused by the marketed 0.12% CHX formula and 3) that these mouthrinses have no negative microbiological effects, and they control total bacterial loads.

Conditions

Interventions

TypeNameDescription
DRUGPlacebo: PCBParticipants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
DRUG0.12%NFParticipants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
DRUG0.03%NFParticipants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
DRUGPATPatients were asked to rinse every 12 hours, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.

Timeline

Start date
2011-09-01
Primary completion
2013-07-01
Completion
2013-07-01
First posted
2014-07-18
Last updated
2014-07-18

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT02194023. Inclusion in this directory is not an endorsement.